![Jason Slingsby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jason Slingsby
Keine laufenden Positionen mehr
Karriereverlauf von Jason Slingsby
Ehemalige bekannte Positionen von Jason Slingsby
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OXFORD BIOMEDICA PLC | Corporate Officer/Principal | 01.01.2015 | 01.05.2023 |
Zytoprotec GmbH
![]() Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Direktor/Vorstandsmitglied | - | - |
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Corporate Officer/Principal | - | - |
InterCel, Inc. | Corporate Officer/Principal | - | - |
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Vorstandsvorsitzender | 01.07.2005 | - |
Gründer | 26.04.2010 | - |
Ausbildung von Jason Slingsby
Imperial College London | Doctorate Degree |
London Business School | Masters Business Admin |
Statistik
International
Vereinigtes Königreich | 4 |
Österreich | 3 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 3 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Communications | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
OXFORD BIOMEDICA PLC | Health Technology |
Private Unternehmen | 4 |
---|---|
InterCel, Inc. | Communications |
Sosei Co. Ltd.
![]() Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
Zytoprotec GmbH
![]() Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Health Technology |
- Börse
- Insiders
- Jason Slingsby
- Erfahrung